Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Aclaris Therapeutics Inc
ACRSCurrent price
1.39 USD
+0.05 USD (+3.73%)
Last closed
1.38 USD
Company
www.aclaristx.com
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NASDAQ
Capitalization
94 782 184 USD
Yield for 12 month
-85.52 %
1Y
3Y
5Y
10Y
15Y
ACRS
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Address: 701 Lee Road, Wayne, PA, United States, 19087
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.84 USDP/E ratio
–Dividend Yield
–Current Year
+31 249 000 USD
Last Year
+29 752 000 USD
Current Quarter
+2 398 000 USD
Last Quarter
+17 570 000 USD
Current Year
+13 168 000 USD
Last Year
+17 792 000 USD
Current Quarter
+558 000 USD
Last Quarter
+11 142 000 USD
Key Figures ACRS
1 year
3 years
5 years
10 years
EBITDA
-117 565 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-31.9 %
PEG Ratio
-0.13
Return On Equity TTM
-48.47 %
Wall Street Target Price
1.84 USD
Revenue TTM
31 119 000 USD
Book Value
1.99 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-5.1 %
Dividend Yield
–
Gross Profit TTM
-60 021 000 USD
Earnings per share
-1.09 USD
Diluted Eps TTM
-1.09 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-248.28 %
Dividend Analytics ACRS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ACRS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ACRS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
35.3605
Price Sales TTM
2.7463
Enterprise Value EBITDA
0.2846
Price Book MRQ
0.546
Financials ACRS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ACRS
For 52 weeks
0.59 USD
10.15 USD
50 Day MA
1.17 USD
Shares Short Prior Month
4 457 886
200 Day MA
1.75 USD
Short Ratio
3.75
Shares Short
3 940 731
Short Percent
6.6 %
BeatStart